STOCK TITAN

Fulgent Genetics (FLGT) SEC Filings, Jul 29, 2025

FLGT NASDAQ

Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.

The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.

Schedule 13G/A
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
other

FAQ

How many Fulgent Genetics (FLGT) SEC filings are available on StockTitan?

StockTitan tracks 101 SEC filings for Fulgent Genetics (FLGT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Fulgent Genetics (FLGT)?

The most recent SEC filing for Fulgent Genetics (FLGT) was filed on November 18, 2026.